TherapeuticsMD (TXMD) Net Shares Issued and Repurchased (2011 - 2025)
TherapeuticsMD's (TXMD) quarterly Net Shares Issued and Repurchased came in at $67000.0 in Q4 2025, up 346.67% on a YoY basis from $15000.0 in Q4 2024, and up 1240.0% quarter-over-quarter from $5000.0 in Q1 2025.
Powered by 
Analysis
TherapeuticsMD (TXMD) Net Shares Issued and Repurchased (2011 - 2025) Analysis & Trends
TherapeuticsMD (TXMD) has reported Net Shares Issued and Repurchased for 15 consecutive years, with $67000.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Net Shares Issued and Repurchased rose 346.67% year-over-year to $67000.0; the trailing twelve-month figure through Dec 2025 stood at $67000.0 (up 346.67% YoY), and the FY2025 full-year result was $67000.0, up 346.67% from the prior year.
- Net Shares Issued and Repurchased rose to $67000.0 in Q4 2025 per TXMD's latest filing, from $5000.0 in the prior quarter.
- Across five years, Net Shares Issued and Repurchased topped out at $177000.0 in Q4 2022 and bottomed at $3.0 in Q1 2024.
- Historically, Net Shares Issued and Repurchased has averaged $62750.4 across 5 years, with a median of $52000.0 in 2022.
- The sharpest annual moves came in 2021 and 2025: Net Shares Issued and Repurchased tumbled 86.3% in 2021, then surged 166566.67% in 2025.
- Over 5 years, Net Shares Issued and Repurchased stood at $101000.0 in 2021, then surged by 75.25% to $177000.0 in 2022, then plunged by 43.5% to $100000.0 in 2023, then slumped by 85.0% to $15000.0 in 2024, then jumped by 346.67% to $67000.0 in 2025.
- According to Business Quant data, Net Shares Issued and Repurchased over the past three periods registered $67000.0, $5000.0, and $15000.0 for Q4 2025, Q1 2025, and Q4 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | - |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | - |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | -3.07 Bn |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | - |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | - |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | - |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | - |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 67,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Dec 31, 2024 | 15,000.00 |
| Mar 31, 2024 | 3.00 |
| Dec 31, 2023 | 100,000.00 |
| Dec 31, 2022 | 177,000.00 |
| Mar 31, 2022 | 37,000.00 |
| Dec 31, 2021 | 101,000.00 |
| Dec 31, 2020 | 737,000.00 |
| Mar 31, 2020 | 636,500.00 |
| Dec 31, 2019 | 4.62 Mn |
| Mar 31, 2019 | 1.04 Mn |
| Dec 31, 2018 | 3.26 Mn |
| Mar 31, 2018 | 2.03 Mn |
| Dec 31, 2017 | 2.27 Mn |
| Mar 31, 2017 | 1.73 Mn |
| Dec 31, 2016 | 1.73 Mn |
| Mar 31, 2016 | 185,500.00 |
| Dec 31, 2015 | 4.69 Mn |
| Mar 31, 2015 | 919,500.00 |